Ranbaxy in-licenses NDDS analgesic molecule from Ethypharm

By Lisa Kerner

Erie, Pa., May 24 - Ranbaxy Laboratories Ltd. said it has entered into a strategic in-licensing agreement with Ethypharm LL India for the Novel Drug Delivery System (NDDS) analgesic, Tramadol 50 mg Flashtab.

Commonly prescribed for severe to moderately severe pain due to trauma, Tramadol is also used as an adjunct therapy in the treatment of cancer, according to a company news release.

Tramadol Flashtab tablets melt rapidly in the mouth without water.

Ethypharm will supply the product to be marketed and distributed by Ranbaxy under the brand name Trambax.

"The introduction of Trambax (Tramadol Flashtab) tablets is part of Ranbaxy's strategy to provide world-class products with NDDS technology to doctors in India bringing rapid pain relief to their patients, regional director for India and Middle East Sanjeev I. Dani said in the release.

"This will further strengthen our portfolio in the pain management segment."

Ranbaxy said it intends to in-license other NDDS products for the Indian market to supplement its portfolio.

Ranbaxy is a generic pharmaceutical company based in Gurgaon, India

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.